Reimagining the FDA, One Shortcut at a Time

When two of medicine’s most outspoken reformers publish a roadmap for the FDA, you expect at least coherence. Instead, we get a curious blend of tech evangelism, selective evidence, and lofty ambitions untethered from the practical messiness of regulation. Let’s just say if this is the revolution, it needs a better peer review — and maybe a clinical trial.